CorMedix Therapeutics shares plunged 28% after the company forecast 2026 revenue of $300-$320 million, below its $310 million reported for 2025. The outlook includes $150-$170 million from DefenCath and $100-$125 million in adjusted EBITDA, disappointing investors after a strong 2025 performance.